There is adequate preclinical data to support the differential biochemical and pharmacological behavior of the currently approved low molecular weight heparins (LMWHs) in the United States. Initial studies on the anti-Xu, anti-lla, and U.S. Pharmacopoeial (USP) potencies have clearly demonstrated differences among these products. Furthermore. the ratios between the unti-X and anti-lla activities vary from one product to another. THis is primarily due to the composition of each product manufactured by using different patented methods. Studies in pharmacologic animal models, using gravimetric dosages or adjusted anti-Xa dosages of the LMWHs. produce product-specific results. The pharmacokinetics and pharmacodynumics of each product also vary markedly and are not predictable on the basis of any pharmacopoeial potency designation. These agents are capable of releasing tissue factor pathway inhibitor (TFPI). an inhibitor of the coagulation process. Its release is also dependent on the type of LMWH. In the This brief review serves to illustrate some of the known differences and similarities between low molecular weight heparin (LMWH) and unfractionated heparin and, specifically, is designed to alleviate confusion harbored by many clinicians regarding the interchangeability of different LMWHs available in the United States. The three U.S. Food and Drug Administration (FDA) approved agents compared are dalteparin (Fragrnin, Pharmacia & Upjohn, Bridgewater. NJ. U.S.A.), enoxaparin (Lovenox, Rhone-Poulenc Rorer, Collegeville, PA, U.S.A.). and ardeparin (Normiflo, Wyeth-Ayerst Laboratories, Philadelphia. PA, U.S.A.). Figure I compares the three available FDA approved LMWHs with respect to molecular weights <2.500 d, the range where relatively lillie anti-Xa or anti-I1a activity is detected. It is noted that approximately 15% of enoxaparin, 4% of dalteparin, and 6% of ardeparin is in this range (1-4). This molecular weight range includes Manuscript S63 United States enoxaprin, dalteparin, and ardeparin have been approved for DVT prophylaxis. Only enoxaparin and dalteparin have been approved for the acute coronary syndrome. Recently the clinical differentiation among these LMWHs has been demonstrated in the treatment of acute coronary syndrome. Similarly, when these drugs are used at high dosages, they are expected to produce product-specific pharmacodynamic effects. It must be noted that while these drugs may be interchangeable at clinically optimized/approved dosages. these drugs are not interchangeable at equivalent anti-Xu dosages. Even at optimized dosages, the clinical provile of each drug may be different. Thus, each of the LMWHs should be considered a distinct entity and their use in a given clinical situation should be validated in proper clinical trials. Key Words: Low molecular weight heparin-Clinical trials-Differentiation-Pharmacodynamics. oligosaccharides with <8 hexose units. This may have therapeutic implications. Figure 2 illustrates that percentage of each preparation that is above the low molecular weight range (i.e., >7,500 d). It is noted that approximately 37% of enoxaparin, 25% of dalteparin, and 35% of ardeparin contain moieties of molecular weight >7,500 d (i.e., heparin moieties in the un fractionated heparin range) (1-4). This molecular weight range includes chain lengths containing >20 hexose units. Such components affect the anti-Xa and anti-Ila activities and may have some implications in the bleeding and heparin-induced thrombocytopenic responses with these drugs. Figure 3 compares the anti factor Xa activity of these three LMWHs. The relative anti-Xa activity is approximately 98 Ulmg for enoxaparin, 148 Ulmg for dalteparin, and 60 Ulmg for ardeparin. Thus, the highest anti-Xu activity of these three compounds is noted with dalleparin, the lowest with ardeparin, and enoxaparin demonstrates activity intermediate between dalteparin and ardeparin (1-4). The anti-Xa activity mayor may not be related to the molecular composition of the LMWH. Manufacturing processing plays a key role in the overall potency of each agent. Figure 4 compares the U.S. Pharmacopoeia (USP) po-
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COMPARISON OF LMWHS
Figure I compares the three available FDA approved
LMWHs with respect to molecular weights <2.500 d, the range where relatively lillie anti-Xa or anti-I1a activity is detected. It is noted that approximately 15% of enoxaparin, 4% of dalteparin, and 6% of ardeparin is in this range (1) (2) (3) (4) 
S63
United States enoxaprin, dalteparin, and ardeparin have been approved for DVT prophylaxis. Only enoxaparin and dalteparin have been approved for the acute coronary syndrome. Recently the clinical differentiation among these LMWHs has been demonstrated in the treatment of acute coronary syndrome. Similarly, when these drugs are used at high dosages, they are expected to produce product-specific pharmacodynamic effects. It must be noted that while these drugs may be interchangeable at clinically optimized/approved dosages. these drugs are not interchangeable at equivalent anti-Xu dosages. Even at optimized dosages, the clinical provile of each drug may be different. Thus, each of the LMWHs should be considered a distinct entity and their use in a given clinical situation should be validated in proper clinical trials. Key Words: Low molecular weight heparin-Clinical trials-Differentiation-Pharmacodynamics. oligosaccharides with <8 hexose units. This may have therapeutic implications. Figure 2 illustrates that percentage of each preparation that is above the low molecular weight range (i.e., >7,500 d). It is noted that approximately 37% of enoxaparin, 25% of dalteparin, and 35% of ardeparin contain moieties of molecular weight >7,500 d (i.e., heparin moieties in the un fractionated heparin range) (1) (2) (3) (4) . This molecular weight range includes chain lengths containing >20 hexose units. Such components affect the anti-Xa and anti-Ila activities and may have some implications in the bleeding and heparin-induced thrombocytopenic responses with these drugs. Figure 3 compares the anti factor Xa activity of these three LMWHs. The relative anti-Xa activity is approximately 98 Ulmg for enoxaparin, 148 Ulmg for dalteparin, and 60 Ulmg for ardeparin. Thus, the highest anti-Xu activity of these three compounds is noted with dalleparin, the lowest with ardeparin, and enoxaparin demonstrates activity intermediate between dalteparin and ardeparin (1) (2) (3) (4) . The anti-Xa activity mayor may not be related to the molecular composition of the LMWH. Manufacturing processing plays a key role in the overall potency of each agent. tency of these three agents. The lowest USP potency is noted with enoxaparin, whereas dalteparin and ardeparin are approximately equal in USP potency (1) (2) (3) (4) . The clinical meaning of this remain s unclear. The rank order of relati ve potency is different in this assay as compared to that obtained in the anti-Xa assay. Thu s. besides the antithrombin (AT) III affinity components responsible for the ant i-Xu activity, other factors may be relevant. Figure 5 illustrates the antithrombotic activity measured in an animal model at equivalent anti-Xa dosages in the intravenous studies (rabbit stasis model) (1) (2) (3) (4) . It is noted that the lowest intravenous antithrombotic acti vity in this model is seen with ardeparin, the highest is noted with dalteparin, and intermediate antithrombotic activity is noted with enoxaparin (1-4). It is clear that the acute intravenous anti thrombotic effe ct is not directly proportional to the anti-Xa effects. Thus, other factors may also be responsible for the overall antithrombotic activity of the LMWHs. Figure 6 demonstrates bleedability with each compound given by the intravenous route, compared to un- fractionated heparin, as measured by a bleeding index . The highest bleeding index (mo st bleeding) is seen with ardeparin, the least with dalteparin, and enoxaparin is intermediate (1) (2) (3) (4) . It is noted that enoxaparin and dalteparin are associated with less bleeding than is noted for unfractionated heparin, whereas with ardeparin, the bleeding index is slightly higher than for unfractionated heparin. At equivalent anti-Xu units. the different LMWHs produce varying effects after intr avenou s administration. Thus, additional factors may be responsible for the antithrornbotic effects of these agents. Figure 7 depicts the same bleeding inde x with each LMWH when given by the sub cutaneous route. The most bleeding is noted with enoxaparin, the least with ardeparin, and intermediate bleeding is observed with unfractionated heparin and dalteparin (1) (2) (3) (4) . In contrast to the intravenous administration study . the relative antithrombotic effects of the various LMWHs differ after subcutaneous administration. This may be related to the bioavailability of these agents. (TFPI) release in nanograms per milliliter with each of these LMWH agents. At equivalent anti-Xa dosages varying amounts of TFPI are released. It is thought that TFPI release is important in rendering significant antithrombotic activity (5) . It is noted from Fig. 8 that enoxaparin and dalteparin are approximately equal in their ability to release TFPI, but they have less TFPI releasing activity than unfractionated heparin (1) (2) (3) (4) ).
LOW MOLECULAR WEIGHT HEPARINS
It appears there may be differences between dalteparin and enoxaparin with respect to cross -reactivity to the antiheparin/platelet factor (PF) 4 antibodies in patients with type II heparin-induced thrombocytopenia (HIT) syndrome and HIT with thrombosis (HITT) following exposure to unfractionated heparin. The cross-reactivity of dalteparin has been reported to be as low as 20% and that of enoxaparin about 37%; others, however, have found much higher cross-reactivity for both agents (6) (7) (8) .
There is no available data for ardeparin. The clinical LOW MOLECULAR WEIGHT HEPARINS BLEEDING· INTRAVENOUS ROUTE significance of this with respect to the development of HIT/HITT with these agents remains unclear (6) (7) (8) .
Whether there is a relationship between the TFPI release and the HIT potential is not known. However, the PF 4 mobilization effects of these agents may be directly related to the HIT potential.
Much confusion exists regarding the anti factor Xa/ antifactor IIa ratios and the differences noted between dalteparin and enoxaparin. A well-defined study using biochemically defined systems to determine the anti-Xa and anti-lla ratios is not available at this time. The values for the ratios vary and are dependent on the assay reagents used, It should be noted that the anti-Xa activity is thought to be highly correlated with inhibition of in vivo thrombus formation and less correlated with prolongation of in vitro coagulation tests such as the activated partial thromboplastin time (aPTT). By contrast, the anti-IIa activity is, of course, associated with antithrombotic activity, but appears to be better correlated with inhibition of in vitro coagulation tests, such as the aPIT, than with the anti-Xa activity (9) . Thus, it is currently thought 
ANTI-Xa / ANTI-IIa RATIO OF VARIOUS LOW MOLECULAR WEIGHT HEPARINS AS MEASURED BY AN AMIDOLYTIC METHOD
that the anti-Xa activity is best correlated with antithrornbotic activity with the use of these agents. However, these agents are in fact multifactorial in their activity and there arc many antithrombotic activities that cannot be measured from the practical standpoint in the clinical laboratory setting (9, 10) . Figure 9 demonstrates the anti-Xa/anti-Ila ratios comparing dalteparin and enoxaparin. The ratio for dalteparin is approximately 2.8 while that for enoxaparin is much higher at about 3.8 (II). The anti-Xu and anti-Ira effects of LMWHs arc largely due to their composition of AT III affinity fractions. However, these may not reflect their pharmacological actions. This, in theory, could mean that the higher anti-Ila activity noted with dalteparin may be associated with more anti thrombotic activity than the lower anti-Ila activity noted with enoxaparin. It is certainly thought that the higher anti-Xa activity with dalteparin, as compared to enoxaparin, is associated with higher anti thrombotic activity (9) . In fact, it was noted at the most recent American College of Chest Physicians (ACCP) Consensus Conference that the clinical significance of this remains unknown and clearly the anti-Xa/ anti-JIa ratio is not related to bleeding (12) .
In addition, it should be noted that the World Health Organization (WHO) standard for the 'anti-Xa/anti-Ila ratio' LMWHs, is 2.5 (II). Also, the College of American Pathologists (CAP) XXXI Consensus Conference on Antithrombotic Therapy recognizes the standard for the anti-Xa/anti-Ila ratio for LMWHs to be 2.5 (13) . Obviously, dalteparin is much closer to the WHO standard ratio than is enoxaparin. However, it may be hypothesized that the lower ratio is associated with more antithrombotic activity, via more desirable anti-lla activity and much enhanced anti-Xa activity. At present this remains unclear (12) .
It is well known that each LMWH product represents a distinct entity with its own pharmacological and chemical profile. The in vitro potency assignments such as the This brief review has served to compare three LMWH agents in an attempt to alleviate much of the confusion that appears to exist regarding similarities and differences between these U.S. FDA licensed products. In particular, there has been marked confusion regarding the 'meaning' of the anti-Xa/anti-lla ratio; indeed, the meaning of this ratio remains unclear, but differences in the ratios certainly do not appear to be associated with bleedability and the higher anti-Ila levels (lower ratios) may be correlated with higher efficacy. For specific clinical indications, each drug should be individually developed.
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SUMMARY anti-Ila potency may only have pharmaceutical value, but limited clinical value. The pharmacological actions of these drugs not only involve the plasmatic actions that are mediated via AT III, but may also be influenced by their direct effects on blood vessels (TFPI release), effects on platelets (selectin inhibition), and white cell functional modulation. 
